Roche: Barclays cuts TP

(CercleFinance.com) - Barclays maintains its 'equal weight' rating on Roche shares, while reducing its target price for them from 250 CHF to 230 CHF, the day after the Swiss healthcare group's Q1 trading update.


"Though Roche's 1Q24 sales report was in-line and guidance was unchanged, the call focused on competitive threats to major franchises", the broker says.

"With Phase III results for Novo Nordisk's Mim8 in hemophilia A imminently expected, we think the stock could be held in a narrow range until then", it adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.